Loading...
Market
What will be the impact of Tryngolza on Ionis' revenue growth for 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Ionis Pharmaceuticals' 2025 annual financial report
Story
Ionis Pharmaceuticals Secures FDA Approval for Tryngolza, Its First Wholly-Owned Drug for Familial Chylomicronemia Syndrome, Lowers Triglycerides
Dec 19, 2024, 10:25 PM
Ionis Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug Tryngolza, designed to treat familial chylomicronemia syndrome, a rare genetic disorder that affects the body's ability to break down fats. This approval marks a significant milestone for Ionis, as it is the company's first wholly-owned drug. The therapy works by lowering triglyceride levels in patients suffering from this condition, which can lead to severe health complications. The FDA's decision was confirmed through various sources, highlighting the importance of this approval for both the company and patients in need of effective treatment options.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Market leader • 33%
Second place • 33%
Third place or lower • 33%
Less than $400 million • 25%
$400 million to $475 million • 25%
$475 million to $550 million • 25%
More than $550 million • 25%
Less than $1,100 million • 25%
$1,100 million to $1,251 million • 25%
$1,251 million to $1,400 million • 25%
More than $1,400 million • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Exceeds $1 billion in sales • 25%
Between $500 million and $1 billion in sales • 25%
Between $100 million and $500 million in sales • 25%
Less than $100 million in sales • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $500 million • 33%
$500 million to $1 billion • 33%
More than $1 billion • 33%